source
- Rapport Therapeutics reports Phase 2 success for J&J-licensed bipolar mania drugRapport Therapeutics announced that its oral investigational drug, which modulates AMPA receptors, has successfully completed a Phase 2 trial in patients with bipolar mania. The study met its prim…
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion, expanding siRNA portfolioMerck KGaA, the German science and technology conglomerate, announced an agreement to purchase UK‑based Silence Therapeutics. The deal is valued at about $1.3 billion and gives Merck access to Sil…